USA flag logo/image

An Official Website of the United States Government

Back

Company Information:

Company Name: Verax Corp
City: Lebanon
State: NH
Zip+4: 03766
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $455,427.00 10
SBIR Phase II $640,930.00 2

Award List:

CONTINUOUS CELL CULTURE FOR MONOCLONAL ANTIBODIES

Award Year / Program / Phase: 1983 / SBIR / Phase I
Agency: HHS
Principal Investigator: Frederick Cahn
Award Amount: $43,073.00

CONTINUOUS CELL CULTURE FOR MONOCLONAL ANTIBODIES

Award Year / Program / Phase: 1984 / SBIR / Phase II
Agency: HHS
Principal Investigator: Frederick Cahn
Award Amount: $434,930.00
Abstract:
The objective for this project is to prove the feasibility of the research plan for a phase ii program to demonstrate a large cost reduction for the "in vitro" production of monoclonal antibodies. according to the applicant's company's system, hybridomas are immobilized in hydrocolloidgels or in… More

THE OBJECTIVE OF THIS PROJECT IS TO DEMONSTRATE THE FEASIBILITY OF EFFICIENTLY PRODUCING BIOCHEMICALS FROM MAMMALIAN FIBROBLASTS BY A NOVEL METHOD OF CONTINUOUS CULTURE WITH IMMOBILIZED CELLS.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Philip g. phillips , PRINCIPAL INVESTIGATOR
Award Amount: $38,378.00
Abstract:
The objective of this project is to demonstrate the feasibility of efficiently producing biochemicals from mammalian fibroblasts by a novel method of continuous culture with immobilized cells. the novelty of this method centers on a unique cell carrier, which allows for a high density of cell… More

THE OBJECTIVE OF THIS PHASE I PROJECT IS TO DEMONSTRATE THE FEASIBILITY OF A NOVEL APPROACH TO CULTURING CELLS IN ORDER TO PRECISELY DETERMINE THEIR RESPONSE TO ENVIRONMENTAL CHANGES.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Philip g. phillips and su , PRINCIPAL INVESTIGATOR
Award Amount: $46,976.00
Abstract:
The objective of this phase i project is to demonstrate the feasibility of a novel approach to culturing cells in order to precisely determine their response to environmental changes. this approach will allow for rapid optimization of culture conditions so that expression of a desired biochemical… More

MATHEMATICAL MODELING OF MAMMALIAN CELLS

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: NSF
Principal Investigator: Nitya G Ray , Director Culture Kinetics Lab
Award Amount: $39,000.00

THE CULTURE ENVIRONMENT IN WHICH A MAMMALIAN CELL IS MAINTAINED CAN PROFOUNDLY INFLUENCE ITS STATE OF DIFFERENTIATION AND ITS LONGEVITY AS WELL AS ITS GROWTH RATEAND PRODUCTIVITY.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Edward g hayman , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The culture environment in which a mammalian cell is maintained can profoundly influence its state of differentiation and its longevity as well as its growth rateand productivity. verax corporation has developed a system for the mass culture of mammalian cells and has chosen large-scale production… More

WITH THE ADVENT OF MONOCLONAL ANTIBODY TECHNOLOGY, TWO THINGS HAVE BECOME INCREASINGLY OBVIOUS: 1.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Amar s tung , PRINCIPAL INVESTIGATOR
Award Amount: $47,000.00
Abstract:
With the advent of monoclonal antibody technology, two things have become increasingly obvious: 1. these moleculeswill be needed in kilogram quantities for the treatment of avariety of malignancies. 2. antibodies of human, and not murine, origin will ultimately be the molecules of choice. verax has… More

THE USE OF IN VITRO PRODUCED MONOCLONAL ANTIBODIES FOR THE TREATMENT OF IMMUNOLOGIC, INFECTIOUS, AND NEOPLASTIC DISEASES IN HUMANS IS PROJECTED TO INCREASE SHARPLY IN THE UPCOMING YEARS.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Amar s tung , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The use of in vitro produced monoclonal antibodies for the treatment of immunologic, infectious, and neoplastic diseases in humans is projected to increase sharply in the upcoming years. verax corporation has developed a novel system for the mass culture of hybridoma cells as well as several… More

MATHEMATICAL MODELING OF MAMMALIAN CELLS

Award Year / Program / Phase: 1987 / SBIR / Phase II
Agency: NSF
Principal Investigator: Nitya G Ray , Director Culture Kinetics Lab
Award Amount: $206,000.00
Abstract:
The recent development of molecular biology, particularly inthe field of recombinant dna technology, gives birth to a new era in medical therapeutics and diagnostics using products from mammalian cell culture. for effective research and clinical use, these products need to be manufactured in large… More

A NOVEL SYSTEM FOR HUMAN HYBRIDOMA CULTURE

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Amar s tung phd
Award Amount: $43,000.00
Abstract:
With the advent of monoclonal antibody technology, it has become clear that there is a growing need to produce human cells and cell products in larger quantities for the treatment of various immunologic, infectious, and neoplasticdiseases. verax corporation has developed a novel system for the mass… More

DEFINED MEDIA FOR CONTINUOUS CULTURE OF MAMMALIAN CELLS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $48,000.00
Abstract:
With the advent of genetic engineering technology, it has become clear that there is a growing need to produce cloned cell products in larger quantities for the treatment of various cardiovascular, immunologic, infectious and neoplastic diseases. verax corporation has developed a novel system for… More

PRODUCTION OF HIV GP-120 PROTEIN

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The terminal nature of hiv infections has prompted demands for large quantities of hiv proteins for research related to understanding the virus and developing therapeutic treatments. verax corporation has developed a unique systemfor the mass culture of mammalian cells in a continuous fluidized bed… More
Back